Revaccination against hepatitis B virus of non-responding and low-responding infants immunised at birth. A parallel evaluation of rubella and tetanus vaccine

Vaccine

Volumn 16, Issue 4, 1998, Pages 399-402

  Belloni, C ^a,c   Tinelli, C ^a   Orsolini, P ^a   Pistorio, A ^a   Avanzini, A ^a   Moretta, A ^a,b   Gulminetti, R ^c   Bogliolo, O ^a   Chirico, G ^a   Rondini, G ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c NONE

Author keywords

HBV; Immunisation; New born; Non responsiveness; Rubella; Tetanus

Indexed keywords

HEPATITIS B VACCINE; RECOMBINANT VACCINE; RUBELLA VACCINE; TETANUS TOXOID;

ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEWBORN; PRIORITY JOURNAL; REVACCINATION; SEROCONVERSION;

EID: 0032007516     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)80917-6     Document Type: Article

References (24)

1. 1 Immunization Practices Advisory Committee Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb. Mortal Wkly Rep. 1991, 40, 1-25.
2. 2 American Academy of Pediatrics Committee on Infectious Diseases, Universal hepatitis B immunization. Pediatrics 1992, 89, 795-800.
3. 3 Rep IT. Serie generale no. 127 legge 27 maggio 1991 no. 165.
4. 4 Jilg, W., Schmidt, M. and Deinhardt, F. Decline of anti-HBs after hepatitis B vaccination and timing of revaccination [letter]. Lancet 1990, 335, 173-174.
5. 5 Orsolini, P., Belloni, C. and Klersy, C. et al. Anti HBV neonatal immunization with recombinant vaccine. Part I. Critical appraisal for a long lived antibody course. Vaccine 1995, 13, 551-554.
6. 6 Hollinger, F.B. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am. J. Med. 1989, 87, 36S-40S.
7. 7 Windebank, K.P., Faux, J.A. and Chapel, H.M. ELISA determination of IgG antibodies to pneumococcal capsular polysaccharides in a group of children. J. Immunol. Meth. 1987, 104, 143-148.
8. 8 Weibel, R.E., Carlson, A.J. Jr, Villarejos, V.M., Buynak, E.B., McLean, A.A. and Hilleman, M.R. Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus. Proc. Soc. Exp. Biol. Med. 1980, 165, 323-326.
9. 9 dBASE III Plus, release 1.0 IBM/MSDOS, Ashton-Tate 1986.
10. 10 Statistics per Windows, release 5.0 (1995), StatSoft, Tulsa, OK.
11. 11 Belloni, C., Orsolini, P. and Martinetti, M. et al. Control of Hepatitis B: evaluation of two different vaccinal schedules in newborns from HBsAg negative mothers. Microbiologica 1993, 16, 237-244.
12. 12 Chirico, G., Belloni, C. and Gasparoni, A. et al. Hepatitis B immunization in infants of hepatitis B surface antigen-negative mothers. Pediatrics 1993, 92, 717-719.
13. 13 Craven, D.E., Awdeh, Z.L. and Kunches, L.M. et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann. Internal Med. 1986, 105, 356-360.
14. 14 Szmuness, W., Stevens, C.E. and Harley, E.J. et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N. Engl. J. Med. 1980, 303, 833-841.
15. 15 Stevens, C.E., Alter, H.J., Taylor, P.E., Zang, E.A., Harley, E.J. and Szmuness, W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N. Engl. J. Med. 1984, 311, 496-501.
16. 16 Dienstag, J.L., Werner, B.G. and Polk, B.F. et al. Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann. Internal Med. 1984, 101, 34-40.
17. 17 Yvonnet, B., Coursaget, P. and Chotard, J. et al. Hepatitis B vaccine in infants from an endemic area: long-term anti-HBs persistence and revaccination. J. Med. Virol. 1987, 22, 315-321.
18. 18 Tan, K.L., Goh, K.T., Oon, C.J. and Chan, S.H. Immunogenicity of recombinant yeast-derived hepatitis B vaccine in nonresponders to perinatal immunization. JAMA 1994, 271, 859-861.
19. 19 Cheng, K.F., Chang, M.H., Lee, C.Y., Huang, L.M., Hsu, H.Y., Lee, P.I. and Chen, C.M. Response to supplementary vaccination with recombinant or plasma hepatitis B vaccine in healthy non-responding children. Vaccine 1994, 12, 899-902.
20. 20 Coursaget, P., Yvonnet, B. and Gilks, W.R. et al. Scheduling of revaccination against hepatitis B virus. Lancet 1991, 337, 1180-1183.
21. 21 Salazor, M., Deulofent, H. and Granja, C. et al. Normal HBsAg presentation and T-cell defect in the immune response of non responders. Immunogenetics 1995, 41, 336-374.
22. 22 Spriggs, D.R. and Koff, W.C. Topics in Vaccine Adjuvant Research. CRC Press, Boca Raton, FL, 1991.
23. 23 Gupta, R.K., Relyveld, E.H., Lindblad, E.B., Bizzini, B., Ben-Efraim, S. and Gupta, C.K. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993, 11, 293-306.
24. 24 Audibert, F.M. and Lise, L.D. Adjuvants: current status, clinical perspectives and future prospects. Immunol. Today 1993, 14, 281-284.